长春高新公告称，公司子公司金赛药业收到美国FDA书面通知，金赛药业注射用GenSci143临床试验申请获得受理。GenSci143是金赛药业自主研发的一款靶向B7-H3与PSMA的双特异性抗体偶联药物（BsADC)，具有靶向化疗和肿瘤免疫双重潜在治疗作用。2025年8月，GenSci143拟用于晚期实体瘤的临床试验申请在中国境内已获得国家药品监督管理局受理。

Core Insights - The article discusses the recent financial performance of a leading company in the technology sector, highlighting significant revenue growth and market expansion strategies [1] Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $5 billion in the last quarter [1] - Net income rose to $1.2 billion, reflecting a 30% increase compared to the previous year [1] Market Expansion - The company has successfully entered three new international markets, contributing to 15% of the overall revenue growth [1] - Strategic partnerships with local firms have been established to enhance market penetration and brand recognition [1] Future Outlook - Analysts predict continued growth, estimating a 20% increase in revenue for the upcoming fiscal year [1] - The company plans to invest $500 million in research and development to drive innovation and maintain competitive advantage [1]